remoxipride
Remoxipride (Roxiam) is an atypical antipsychotic (although according to some sources it is a typical antipsychotic) which was previously used in Europe for the treatment of schizophrenia and acute mania but was withdrawn due to toxicity concerns (incidence of aplastic anemia in 1/10,000 patients). It was initially launched by AstraZeneca in 1990 and suspension of its use began in 1993. Remoxipride acts as a selective D2 and D3 receptor antagonist and also has high affinity for the sigma receptor, possibly playing a role in its atypical neuroleptic action.
Chemical data
- Formula
- C16H23BrN2O3
- Molecular weight
- 371.27 g/mol
- IUPAC name
- 3-bromo-N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-2,6-dimethoxybenzamide
via PubChem
Research
385 papers- Clinical pharmacokinetics of remoxipride.Acta psychiatrica Scandinavica. Supplementum · 1990
- Remoxipride. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in schizophrenia.Drugs · 1990
- Pharmacology of the atypical antipsychotic remoxipride, a dopamine D2 receptor antagonist.CNS drug reviews · 2001
- Overcoming the neuroleptic-induced deficit syndrome: clinical observations with remoxipride.Acta psychiatrica Scandinavica. Supplementum · 1994
- Biochemical pharmacology of the atypical neuroleptic remoxipride.
Article
3 sectionsContents
- See also
- References
- External links
Remoxipride (Roxiam) is an atypical antipsychotic (although according to some sources it is a typical antipsychotic) which was previously used in Europe for the treatment of schizophrenia and acute mania but was withdrawn due to toxicity concerns (incidence of aplastic anemia in 1/10,000 patients). It was initially launched by AstraZeneca in 1990 and suspension of its use began in 1993. Remoxipride acts as a selective D2 and D3 receptor antagonist and also has high affinity for the sigma receptor, possibly playing a role in its atypical neuroleptic action.
Due to its short half-life twice daily (bid) dosing is required, although a once-daily controlled-release tablet has been developed. There was some interest in its use in the treatment of treatment-resistant schizophrenia.